Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer.
about
Metabolic Imaging in Prostate Cancer: Where We AreAge-related increase in cross-sensory noise in resting and steady-state cerebral perfusion.MR spectroscopic imaging: principles and recent advances.Sparse spectral deconvolution algorithm for noncartesian MR spectroscopic imaging.Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancerBISTRO: an outer-volume suppression method that tolerates RF field inhomogeneity.Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors.Proton magnetic resonance spectroscopy: technique for the neuroradiologist.Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging.Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients.Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 Tesla for characterization of differences in metabolite levelsQuantification of bone marrow water and lipid composition in anterior cruciate ligament-injured and osteoarthritic knees using three-dimensional magnetic resonance spectroscopic imaging.Three-dimensional MR spectroscopic imaging using adiabatic spin echo and hypergeometric dual-band suppression for metabolic mapping over the entire brain.Recent advances in magnetic resonance neurospectroscopy.Estimation of metabolite T1 relaxation times using tissue specific analysis, signal averaging and bootstrapping from magnetic resonance spectroscopic imaging data.Arterial spin-labeling in routine clinical practice, part 1: technique and artifacts.Quantitative assessment of bone marrow edema-like lesion and overlying cartilage in knees with osteoarthritis and anterior cruciate ligament tear using MR imaging and spectroscopic imaging at 3 Tesla.Improved half RF slice selectivity in the presence of eddy currents with out-of-slice saturationClinical application of magnetic resonance spectroscopy of the liver in patients receiving long-term parenteral nutrition.Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.Dual-band water and lipid suppression for MR spectroscopic imaging at 3 TeslaJ-difference lactate editing at 3.0 Tesla in the presence of strong lipids.Phased array 3D MR spectroscopic imaging of the brain at 7 TPost-processing correction of the endorectal coil reception effects in MR spectroscopic imaging of the prostate.A clinical comparison of rigid and inflatable endorectal-coil probes for MRI and 3D MR spectroscopic imaging (MRSI) of the prostateAnalysis of metabolic indices in regions of abnormal perfusion in patients with high-grade glioma.Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla.Using network science to evaluate exercise-associated brain changes in older adults.Prostate MRI and 3D MR spectroscopy: how we do itProstate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging.Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection.Multimodal wavelet embedding representation for data combination (MaWERiC): integrating magnetic resonance imaging and spectroscopy for prostate cancer detection.Neurologic 3D MR spectroscopic imaging with low-power adiabatic pulses and fast spiral acquisition.Repeatability of edited lactate and other metabolites in astrocytoma at 3T.Magnetic resonance imaging and spectroscopic imaging of prostate cancer.Implementation of 3 T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for gliomas patientsAcute effect of a high nitrate diet on brain perfusion in older adults.3D sensitivity encoded ellipsoidal MR spectroscopic imaging of gliomas at 3T.Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.
P2860
Q28074429-579D66A4-B376-40AF-A70B-8DDCB347912CQ30478823-BB8CF642-57DC-4713-9F34-0E0399C5182BQ30578725-91362459-AA1F-4415-BCDB-A219A47A51E6Q30598999-CF7E1988-C3AD-4D56-BC3D-F8505CB80219Q30606336-A968723B-56B9-4F91-A413-4CD6106E4296Q30653021-50DA7FC7-D38E-4A6C-A278-C698FEC7E4C1Q30657481-A66C87DA-A3CB-449D-9D9F-EAB0E43AD459Q30660397-46862BBE-B321-410F-BED9-82C1E8168DF7Q30667043-08E9F6B2-CD6C-445B-A13D-C2AC1E9E8730Q30717807-D8D22E2B-03AE-4A13-AAAD-EFA9782DC16CQ30831591-1B6A8679-05EB-4F6D-BD67-A2E36ABE2FE5Q31034708-9DCBAAA3-9F4B-4D00-BB8D-4B997F1493EBQ31042659-0AD0A6E3-6D3B-4090-B662-9DEE25B747D9Q31117145-047953F0-9F02-4349-A4C1-49F9E702839DQ31117277-235CBB2C-8AE2-49A8-8786-1D04944FC8AAQ31150843-2A7E7BE6-BC59-4E40-8CDB-B4E7E34AC192Q31166098-1BFAD42A-450A-478D-A9BF-053FAD104068Q33421866-B0C3D444-5F41-45CC-BD86-4C5F2E99EEDAQ33479921-7DC4A8AD-FD26-434D-A0F1-3FD0BDADEB9AQ33574572-0DA7C104-BEB9-4C4F-89A2-BF00858C0345Q33590849-A0515133-C6B0-43E3-B4B3-4D2235239FEFQ33635821-A4D00E4F-EF3F-4F65-83EE-975016ED18BBQ33650085-2BF88A83-6235-4484-B177-3F26F1F2BCAFQ33683563-AE2E36B9-6976-4B82-8EEE-9694B4E56F47Q33704052-CF730304-97B2-442A-8687-D5C704EE68CBQ33793833-17AEE16C-5B60-4545-BA23-0BC9A96D4DFDQ33849173-6E602576-C9D6-4F2B-8D12-7EE3DDF6BB20Q33946151-62A5E677-3E07-4211-B16E-E9559325EAE9Q33954515-1FC2ADA3-3293-4D83-988F-B9937222CF2FQ33964345-D21AF8F0-FD1D-48D3-BEAA-3B1E5E887463Q34017719-C8616AF4-23A5-4011-AC9D-4A9EBB3F8A3BQ34035596-68C3D042-874B-46CE-86EC-B4D05EAF031CQ34107466-6DCAD83B-44D5-48B7-AC8F-B6D3D407F3A7Q34246635-1F56C27D-1704-48EC-8326-77AB461BFF6BQ34311094-6F94EE79-7F7E-4E65-99BB-00B97069DE2EQ34440284-04C17B27-E5A6-43BA-AF96-AC028FA26776Q34478785-9DF42EEA-97EC-4375-B851-96FD0189C221Q34498041-E9912116-B47D-464C-B8B5-B4AA498F1D3DQ34498046-26DB4E50-0351-471A-88A5-BBD57CE9764FQ34498073-19B5CCE9-EA1D-454F-8D19-0F08FD4271D3
P2860
Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer.
@en
type
label
Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer.
@en
prefLabel
Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer.
@en
P2093
P2860
P1476
Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer.
@en
P2093
D B Vigneron
J Kurhanewicz
N Sailasuta
P2860
P356
10.1002/(SICI)1522-2594(200001)43:1<23::AID-MRM4>3.0.CO;2-E
P577
2000-01-01T00:00:00Z